tiprankstipranks
Advertisement
Advertisement

TRDA Stock Latest News

Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
Company AnnouncementsEntrada Therapeutics Highlights Transformational Year and Pipeline Progress
6d ago
8K
TRDA
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
17d ago
NVS
TRDA
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
17d ago
TRDA
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
PremiumThe Fly
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
18d ago
TRDA
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
PremiumRatings
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
18d ago
TRDA
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
PremiumThe FlyEntrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
18d ago
TRDA
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
Premium
Company Announcements
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
18d ago
8K
TRDA
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
Premium
The Fly
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
2M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
2M ago
TRDA
Entrada Therapeutics management to meet with Oppenheimer
PremiumThe Fly
Entrada Therapeutics management to meet with Oppenheimer
2M ago
TRDA
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
PremiumRatings
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
3M ago
TRDA
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
PremiumThe FlyEntrada Therapeutics price target raised to $19 from $13 at Roth Capital
3M ago
TRDA
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
Premium
The Fly
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
3M ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
Premium
Ratings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
3M ago
TRDA
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
PremiumRatings
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
3M ago
TRDA
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
PremiumThe Fly
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
3M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
3M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
PremiumThe Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
3M ago
TRDA
Entrada Therapeutics initiated with an Outperform at Oppenheimer
PremiumThe FlyEntrada Therapeutics initiated with an Outperform at Oppenheimer
4M ago
TRDA
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
Premium
Ratings
Entrada Therapeutics: Advancing DMD and DM1 Pipeline with Emerging Ophthalmology Assets Supports Buy Rating and $20 Target
4M ago
TRDA
Entrada Therapeutics highlights RNA pipeline progress and outlook
Premium
Company Announcements
Entrada Therapeutics highlights RNA pipeline progress and outlook
5M ago
8K
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >